A recent shift in the drug product environment for Africa has seen a score of new products being developed specifically for diseases of the developing world, creating new challenges for regulators in Africa and elsewhere.
The participation of many organisations and countries in the development of new neglected disease products is a remarkable and welcome change from past decades of inertia and neglect. However,
